Krystal Biotech Inc., of Pittsburgh, a gene therapy company developing treatments for patients suffering from dermatological diseases, said it entered a securities purchase agreement with Frazier Healthcare Partners for the private placement of 625,000 shares at $16 each, which will yield gross proceeds of $10 million. Shares of Krystal (NASDAQ:KRYS) closed Friday at $16.26, up 83 cents.